kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human PD-1 / PDCD1 Protein, Fc Tag (HPLC-verified), low endotoxin,100µg  

Recombinant Human PD-1 / PDCD1 Protein, Fc Tag (HPLC-verified), low endotoxin,100µg

Recombinant human PD-1 / PDCD1 Protein, Leu 25 - Gln 167, produced in human 293 cells (HEK293), HPLC-verified, low endotoxin, Fc Tag, low endotoxin (MALS Verified)

Recombinant Human Protein, PDCD1, PD1, CD279, SLEB2

More details


Availability: within 7 days

396,00 €

Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Recombinant Human PD-1, Fc Tag, low endotoxin (PD1-H5257) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # NP_005009.2).
N-terminal Sequence Analysis: Leu 25

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 42.1 kDa. The protein migrates as 56-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 0.1 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 24 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "In vivo and autopsy validation of alpha-synuclein seeding activity using RT-QuIC assay in the gastrointestinal tract of patients with Parkinson's disease"
Shin, Han, Kim et al
Parkinsonism Relat Disord (2022) 103, 23-28
(2) "Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis"
Gao, Zhang, Liu et al
Ann Hematol (2022)
(3) "Lichenoid dermatitis preceding Stevens-Johnson syndrome in a patient treated with nivolumab"
Potts, Lee, Hilliard
BMJ Case Rep (2022) 15 (8)
Showing 1-3 of 23705 papers.


(1) "Heterocyclic compounds as immunomodulators"
Authors: L Wu, J Li, W Yao
Journal: US10669271B2 2020
Application: Binding Assay
(2) "Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity"
Authors: Wang Y, Ni H, Zhou S, et al.
Journal: Cancer Immunol Immunother 2020
Application: Flow cytometry
(3) "Heterocyclic compounds as immunomodulators"
Authors: L Wu, F Zhang, S Mei, et al.
Journal: US10669271B2 2020
Application: Binding Assay
Showing 1-3 of 12 papers.

The following products could also be interesting for you: